Jimbo50
8 minutes ago
‘The treatment, labeled Anavex 2-73 and named blarcamesine, was even more effective, nearly 50%, within a smaller subgroup. It may also be effective in treating a wide range of CNS disorders. If so, the potential for market value tops the $20 billion mark for annual sales. Sales may begin soon. The